In a research report issued today, Wedbush analyst David Nierengarten reiterated an Outperform rating on Sunesis Pharmaceuticals (SNSS) with a $10 price target, as the company should be unblinding …
In a research report released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Sunesis Pharmaceuticals (SNSS) with a $15 price …
